Microbio is thrilled to celebrate its four-year anniversary today (Thursday, 21 July 2022). This
day marks four years of hard work and determination by the talented, growing team making
positive contributions to the health of people everywhere.

Microbio has gone from strength to strength in its first four years.

Recent international achievements include the clearance to sell Microbio’s flagship test,
InfectID-BSI, in Europe. This closely followed the company’s debut at the 32nd European
Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Lisbon, Portugal where
Microbio representatives presented posters.

Closer to home, Microbio moved into new headquarters at Brisbane’s Translational Research
Institute (TRI) in 2021. This move coincided with Microbio shifting its focus from discovery to
application of its InfectID suite of tests in the community. The TRI facilities will also help to set
up domestic manufacturing capabilities.

Staff numbers have grown with the company, from the two founders to a diverse, high-performing team of 14 full- and part-time employees. An increasing number of overseas consultants and advisers are joining the exceptional team.

As Microbio continues to achieve national and international recognition, the company has
benefitted from the services of internationally based consultants and attracted a number of
high-profile shareholders. The scale-up recently restructured to an unlisted public company,
backed by more than 50 shareholders.

The company’s success to date would not have been possible without the incredible talent
and dedication of Microbio’s passionate staff. Thank you to all staff that have been a part of
this journey during the last four years.

Microbio is proud of what it has accomplished and looks forward to many more years of
research and innovation to improve health and wellbeing around the world.

Queensland biotechnology company Microbio expects clinical evaluation trials of its InfectID-BSI tests to be completed next month, prior to launching in the European market.

US based Landrich Group is managing the trials at four locations in the USA, South America, India and Australia, undertaking a performance evaluation of Microbio InfectID assays.

Read more in the media release: 220412_Independent assessment of Microbio’s BSI test expected to be completed in May

Microbio is pleased to announce that following positive domestic pilot study results, its market entry plans for its flagship InfectID-BSI test, which has the potential for significant improvement in detecting bloodstream infection and sepsis, the world’s biggest killer.

Bloodstream infection (BSI) and sepsis result in 11 million deaths annually, killing more people than all forms of
cancer. InfectID-BSI is an in vitro diagnostic test which significantly improves patient outcomes by telling clinicians
within three hours of taking a blood sample which infection to treat.

Read more in the media release: 220328_Microbio_announces_capital_raise_to_launch_revolutionary_bloodstream_infection_test_in_Europe

Microbio has moved into new laboratories at Brisbane’s Translational Research Institute (TRI) with the aim of eventually setting up domestic manufacturing capability.

More information can be found in the media release.


Microbio is pleased to share this profile published in The Yield, Spoke Corporate’s Investor and Industry News. Author Simon Shepherdson has perfectly captured Microbio’s exciting history and big plans for the future. https://spokecorporate.com/diagnostic-technology-set-to-change-the-world/

Microbio is pleased to share the Case Study published by Life Sciences Queensland detailing the recent Federal Government Accelerating Commercialisation Grant and commercialisation progress of its pathogen detection products. Read more at: https://www.lsq.com.au/case-study/microbio-new-diagnostic-tests-to-improve-the-identification-of-pathogens/

Microbio Pty Ltd, an Australian-owned biotech company has been awarded a Federal Government Accelerating Commercialisation Grant to commercialise Microbio’s InfectID-Blood Stream Infection (BSI) diagnostic assay. Read more in the full media release.


Contact us

Complete this form to request more information on purchasing InfectID, including the COVID-19 Replicating assay, new product developments, or other enquiries.
  • This field is for validation purposes and should be left unchanged.